Impact of document type on reporting quality of clinical drug trials: A comparison of registry reports, clinical study reports, and journal publications

BMJ (Online)

Volumn 344, Issue 7838, 2012, Pages

  Wieseler, Beate ^a   Kerekes, Michaela F ^a   Vervoelgyi, Volker ^a   McGauran, Natalie ^a   Kaiser, Thomas ^a  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL RESEARCH; CLINICAL STUDY; CODING; DATA ANALYSIS; DOCUMENTATION; MEDICAL DECISION MAKING; MEDICAL INFORMATION SYSTEM; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; REGISTER; RETROSPECTIVE STUDY; COMPARATIVE STUDY; DRUG SCREENING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH; STANDARD;

DRUG EVALUATION; PERIODICALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RESEARCH REPORT; RETROSPECTIVE STUDIES;

EID: 84857127828     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d8141     Document Type: Article

References (41)

1. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 2000;356:1228-31.
2. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5.
3. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
4. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 2009;1:MR000006.
5. Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737.
6. McGauran N, Wieseler B, Kreis J, Schuler YB, Kolsch H, Kaiser T. Reporting bias in medical research - a narrative review. Trials 2010;11:37.
7. Dickersin K, Rennie D. Registering clinical trials. JAMA 2003;290:516-23. (Pubitemid 37448502)
8. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004;351:1250-1. (Pubitemid 39296312)
9. New York State Attorney General. Settlement sets new standard for release of drug information. 2004. www.oag.state.ny.us/media-center/2004/aug/aug26a-04. html.
10. Attorney General of the State of New York. In the matter of GlaxoSmithKline and SmithKline Beecham Corporation: assurance of discontinuance pursuant to executive law section 63, subdivision 15 and appendices [online]. 2004. www.ag.ny.gov/media-center/2004/ aug/aug26a-04-attach2.pdf.
11. International Federation of Pharmaceutical Manufacturers and Associations. Joint position on the disclosure of clinical trial information via clinical trial registries and databases. 2009. http://clinicaltrials.ifpma.org/ clinicaltrials/fileadmin/files/pdfs/EN/November-10- 2009-Updated-Joint-Position- on-the-Disclosure-of-Clinical-Trial-Information-via- Clinical-Trial-Registries- and-Databases.pdf.
12. Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ 2005;330:956-8. (Pubitemid 40592318)
13. Food and Drug Administration. FDA amendments act (FDAAA) of 2007: public law No. 110-85 § 801. 2007. http://frwebgate.access.gpo.gov/cgi-bin/getdoc. cgi?dbname=110- cong-public-laws&docid=f:publ085.110.pdf.
14. Wood AJJ. Progress and deficiencies in the registration of clinical trials. N Engl J Med 2009;360:824-30.
15. European Commission. List of fields contained in the 'EudraCT' clinical trials database to be made public, in accordance with article 57(2) of regulation (EC) No 726/2004 and its implementing guideline 2008/c168/021. 2009. http://ec.europa.eu/health/files/eudralex/ vol-10/2009-02-04-guideline-en.pdf.
16. European Commission. List of fields to be made public from EudraCT for paediatric clinical trials in accordance with article 41 of regulation (EC) no 1901/2006 and its implementing guideline 2009/C28/01. 2009. http://ec.europa.eu/ health/files/eudralex/vol-10/2009-02- 04-guidelines-paed-en.pdf.
17. Turner EH. Closing a loophole in the FDA Amendments Act. Science 2008;322:44-6.
18. Wieseler B, McGauran N, Kaiser T. Finding studies on reboxetine: a tale of hide and seek. BMJ 2010;341:c4942.
19. Godlee F. We want raw data, now. BMJ 2009;339:b5405.
20. Sawicki PT, Bastian H. German health care: a bit of Bismarck plus more science. BMJ 2008;337:a1997.
21. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions . Version 5.0.1. Cochrane Collaboration, 2011.
22. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
23. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
24. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005;365:1159-62. (Pubitemid 40417566)
25. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 2010;340:c723.
26. Reveiz L, Cortes-Jofre M, Asenjo Lobos C, Nicita G, Ciapponi A, Garcia-Dieguez M, et al. Influence of trial registration on reporting quality of randomized trials: study from highest ranked journals. J Clin Epidemiol 2010;63:1216-22.
27. Simera I, Moher D, Hirst A, Hoey J, Schulz KF, Altman DG. Transparent and accurate reporting increases reliability, utility, and impact of your research: reporting guidelines and the EQUATOR network. BMC Med 2010;8:24.
28. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Expert Working Group. ICH harmonised tripartite guideline: structure and content of clinical study reports E3; current step 4 version. 1995. www.ich.org/fileadmin/Public-Web-Site/ICH- Products/Guidelines/Efficacy/E3/Step4/E3- Guideline.pdf.
29. Ghersi D, Pang T. En route to international clinical trial transparency. Lancet 2008;372:1531-2.
30. Reveiz L, Chan AW, Krleza-Jeric K, Granados CE, Pinart M, Etxeandia I, et al. Reporting of methodologic information on trial registries for quality assessment: a study of trial records retrieved from the WHO search portal. PLoS One 2010;5:e12484.
31. Chan AW. Bias, spin, and misreporting: time for full access to trial protocols and results. PLoS Med 2008;5:e230.
32. Miller JD. Registering clinical trial results: the next step. JAMA 2010;303:773-4.
33. Strengthening the credibility of clinical research. Lancet 2010;375:1225.
34. Food and Drug Administration. Clinicaltrials.gov protocol registration system: US public law 110-85. 2010. http://prsinfo.clinicaltrials.gov/fdaaa. html.
35. Tse T, Williams RJ, Zarin DA. Reporting "basic results" in ClinicalTrials.gov. Chest 2009;136:295-303.
36. European Commission. Implementing technical guidance - List of fields for result-related information to be submitted to the 'EUDRACT' clinical trials database, and to be made public, in accordance with article 57(2) of Regulation (EC) No 726/2004 and article 41 of Regulation (EC) No 1901/2006 and their implementing Guidelines 2008/C168/02 and 2009/C28/01. 2010. http://ec.europa.eu/ health/files/clinicaltrials/technical-guidance-en. pdf.
37. European Commission. Annex 1: Structure of data to be collected for inclusion of results in EudraCT and their making public in the EU Clinical Trials Register. 2010. http://ec. europa.eu/health/files/clinicaltrials/table- en.pdf.
38. (PhRMA). PRaMoA. ClinicalStudyResults.org Transition Notification Announcement: Pharmaceutical Research and Manufacturers of America, 2011.
39. Kaiser T, Kerekes MF, Wieseler B. Industry clinical trial registries as a data source for systematic reviews. In: Abstracts of the 17th Cochrane Colloquium Singapore; 11-14 October 2009; Singapore, Singapore. 2009. www.imbi.uni-freiburg.de/OJS/cca/index.php/ cca/article/view/8108.
40. Lefebvre C, Manheimer E, Glanville J. Searching for studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions . Version 5.1.0. Cochrane Collaboration, 2011.
41. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65. (Pubitemid 38669189)